DaVita DVA · NYSE
$181.63 +1.33% (+$2.38)
Summary
69 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 19% a year over the last 3 years.
- The share price is below the Bulios Fair Price.
- It bought back its own shares for $1.79B in the last fiscal year, 16% of its market value.
- Out of every 100 USD of revenue, 11 USD is left as free cash.
What to watch
- Repaying its net debt would take 3.7 years of operating profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapPrice against the Bulios Fair Price
P/E against its own last 5 years
P/E against the industry (Medical - Care Facilities)
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 13.6 USD for 1 USD of yearly profit. Over the last five years it was 13.4 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 3.4% a year over 5 years. Over the last 3 years it grew by 5.5% a year. For the next fiscal year analysts expect revenue to grow by 3.4%. Earnings per share grew by 19% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 69 USD
- Sales and administration 16 USD
- Taxes and other 9.0 USD
- Net profit 6.0 USD
Net profit, industry median (Medical - Care Facilities) 21 USD
Out of every 100 USD of revenue, 6.0 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 6.7 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 10
- Hold 12
- Sell 1
Today's price within the analysts' price targets
The average target of $235.67 is 30% above today's price. 43% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- U S Dialysis And Related Lab Services 100%
By region
The company reports no revenue by region.
U S Dialysis And Related Lab Services brings in 100% of revenue.
Segments in detail